Literature DB >> 2505013

Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide.

F E Ashton1, J A Ryan, F Michon, H J Jennings.   

Abstract

The protective properties of antibodies induced by immunization of mice with a conjugate of tetanus toxoid and the N-propionyl derivative of group B meningococcal polysaccharide (N-Pr-GBMP-TT) have been investigated. Mice immunized with the conjugate produced antibodies which were bactericidal for Neisseria meningitidis strains B:2b:P1.Ham and B:15:P1.16. Passive protection studies indicated that the conjugate serum completely eliminated or reduced considerably levels of bacteremia by the same strains in mice. There was no bactericidal activity or passive protection against a strain of N. meningitidis C:2b:P1.2. Following absorption of the conjugate serum with GBMP the non-absorbed antibody, directed to N-Pr-GBMP, was bactericidal and protected mice against bacteremia with group B meningococci. Thus N-Pr-GBMP antibodies which do not bind to the GBMP are protective in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2505013     DOI: 10.1016/0882-4010(89)90087-9

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  16 in total

1.  Specificity of the immune response to a modified group B meningococcal polysaccharide conjugate vaccine.

Authors:  Samuel Moore; Esmé K Farley; Peter C Fusco; Francis Michon
Journal:  Clin Vaccine Immunol       Date:  2006-11-01

2.  Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein.

Authors:  N Cadieux; M Plante; C R Rioux; J Hamel; B R Brodeur; D Martin
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Molecular analysis of anti-N-propionyl Neisseria meningitidis group B polysaccharide monoclonal antibodies.

Authors:  Gregory R Moe; Apurva Dave; Dan M Granoff
Journal:  Mol Immunol       Date:  2005-09-02       Impact factor: 4.407

4.  Anti-idiotypic antibody as a potential candidate vaccine for Neisseria meningitidis serogroup B.

Authors:  In Ho Park; Ju Ho Youn; In-Hong Choi; Moon H Nahm; Se Jong Kim; Jeon-Soo Shin
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Activity and cross-reactivity of antibodies induced in mice by immunization with a group B meningococcal conjugate.

Authors:  D Coquillat; J Bruge; B Danve; M Latour; C Hurpin; D Schulz; P Durbec; G Rougon
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Epitopes recognized by a nonautoreactive murine anti-N-propionyl meningococcal group B polysaccharide monoclonal antibody.

Authors:  Gregory R Moe; Apurva Dave; Dan M Granoff
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

7.  Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.

Authors:  Dan M Granoff; Jo Anne Welsch; Sanjay Ram
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

Review 8.  Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

Authors:  J Diaz Romero; I M Outschoorn
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

9.  Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching.

Authors:  Hilde-Kari Guttormsen; Lawrence C Paoletti; Keith G Mansfield; Wojcieck Jachymek; Harold J Jennings; Dennis L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-31       Impact factor: 11.205

10.  Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides.

Authors:  Simona Gallorini; Francesco Berti; Giuseppe Mancuso; Roberta Cozzi; Marco Tortoli; Gianfranco Volpini; John L Telford; Concetta Beninati; Domenico Maione; Andreas Wack
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.